Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Copaxone 40mg Generic At-Risk Launch Anticipated As Soon As February

Feb 01 2017

• By Brenda Sandburg

chess

Related Content

Fate Of Copaxone 40mg Patents Depends On Courts After PTAB Rejection

Dec 13 2016

Related Companies

Teva Pharmaceutical Industries Ltd.

Novartis AG

Momenta Pharmaceuticals, Inc.

Novartis AG

Amneal Pharmaceuticals, Inc.

Dr. Reddy's Laboratories Ltd.

Viatris Inc.

Byondis B.V.

Pfizer Inc.

Additional Topics

United States Policy Legal Issues Intellectual Property Generic Drugs BioPharmaceutical

More from Policy & Regulation

More from Generics Bulletin

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window